Improvement of FR901379 production by mutant selection and medium optimization.
FR901379 (WF11899A) is a novel echinocandin type of lipopeptide antibiotic produced by Coleophoma empetri F-11899. Micafungin (FK463) is derived from the chemical modification of deacylated FR901379. In the present paper, we performed seven generation's strain-breeding, beginning with a wild type, was performed. Selection medium for screening and production medium for high FR901379 production were designed. Sodium chloride content in the selection plate was affected to FR901379 production and shrinkage of the colony size was observed in high producing strains. As selection markers, large colony-shrinking rate and large inhibition circle in the agar-piece method using C. albicans was selected. Using CMA medium with high sodium chloride, 3 mutants, M-1 to M-3, have achieved a high FR901379 production and M-3 showed 5.0 U/mL, while 1.0 U/mL of production was achieved in wild type strain. A-2 medium supplemented with 6% of soluble starch as a carbon source and 0.6% of ammonium sulfate as nitrogen source was also further effective for mutant screening. The FR901379 production of mutant M-4 (fourth generation) increased until 16.0 U/mL. The concentration of the phosphate salt in the medium seemed to inhibit the growth so as to extend the culture period. When the A-3 medium supplemented with low concentration of phosphate salt and magnesium sulfate as a sulfate source was designed and used, mutants with improved production were successively obtained. Finally, variant strain M-7 showed 30.0 U/mL of production, which was about 30 times higher than that of the wild strain.
Kanda
Munekazu
M
Fermentation and Biotechnology Laboratories, Astellas Pharma Inc., 156 Nakagawara, Kiyosu, Aichi 452-0915, Japan.
Tsuboi
Masaru
M
Sakamoto
Kazutoshi
K
Shimizu
Shiho
S
Yamashita
Michio
M
Honda
Hiroyuki
H
D001203:Ascomycota / Q000145:classification / Q000235:genetics* / Q000378:metabolism*; D019149:Bioreactors / Q000382:microbiology*; D018929:Cell Culture Techniques / Q000379:methods*; D024861:Genetic Enhancement / Q000379:methods*; D009154:Mutation; D010456:Peptides, Cyclic / Q000302:isolation & purification* / Q000378:metabolism*; D013045:Species Specificity
C110368:FR 901379; D010456:Peptides, Cyclic